90岁及以上患者抗凝治疗与静脉血栓栓塞症:RIETE登记数据
≥90岁患者更多存在制动、慢性心衰、贫血、肾功能不全或痴呆,99.6%接受抗凝治疗;3个月内26例VTE复发、116例大出血、564例死亡;初始表现为PE者PE死亡多于致命性出血(76 vs 19),孤立DVT者相反(2 vs 11)。
要点
- ≥90岁VTE患者占RIETE登记3.4%,多伴制动、心衰、贫血、肾功能不全或痴呆。
- ≥90岁患者99.6%接受抗凝,3个月内大出血116例、死亡564例、VTE复发26例。
- 初始PE者PE死亡超过致命性出血(76 vs 19),孤立DVT者出血死亡更多(11 vs 2)。
核心结论
- ≥90岁VTE患者抗凝治疗结局因初始VTE表现不同而异,可能提示需要不同的管理策略。
- 需要临床试验评估按初始VTE表现确定的最佳抗凝疗程,以减少该人群的超额死亡。
研究设计与样本
- 研究为RIETE ongoing全球观察性登记分析,纳入客观确认的急性VTE患者。
- 比较≥90岁与<90岁患者基线特征、治疗及抗凝前3个月VTE复发、出血和死亡结局。
主要发现
- ≥90岁患者男性、癌症或近期手术比例较低,制动、慢性心衰、贫血、肾功能不全或痴呆比例较高。
- ≥90岁患者99.6%接受抗凝治疗。
- ≥90岁患者前3个月26例VTE复发、116例大出血、564例死亡。
- 初始PE的≥90岁患者PE死亡76例、致命性出血19例;初始孤立DVT者PE死亡2例、致命性出血11例。
关键数值与推荐
- ≥90岁VTE患者占RIETE登记3.4%(3,262/96,701)。
- ≥90岁患者抗凝治疗率99.6%。
- ≥90岁患者前3个月VTE复发26例、大出血116例、死亡564例。
- 初始PE者PE死亡76例 vs 致命性出血19例;初始孤立DVT者PE死亡2例 vs 致命性出血11例。
临床怎么用
- 对≥90岁VTE患者应评估制动、心衰、贫血、肾功能不全和痴呆等共存情况。
- 初始表现为PE的≥90岁患者抗凝期间需关注PE致死风险,孤立DVT者需关注致命性出血风险。
- 该人群抗凝疗程可能需要根据初始VTE表现个体化,但有待临床试验验证。
局限性
- 原文为观察性登记分析,未报告随机对照试验证据。
- 原文未报告≥90岁患者与<90岁患者结局比较的校正效应值或统计学检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Age is a major risk factor for venous thromboembolism (VTE), yet patients aged ≥90 years are under-represented in clinical trials of anticoagulant therapy. The objectives were to describe and compare patient clinical characteristics, treatments, and outcomes (VTE recurrence, bleeding, and mortality) during the first 3 months of anticoagulation between VTE patients aged ≥90 years and those aged <90 years. METHODS: We analyzed data from the Registro Informatizado Enfermedad TromboEmbὀlica (RIETE), an ongoing global observational registry of patients with objectively confirmed acute VTE. RESULTS: From January 2001 to October 2022, 96,701 patients were registered in RIETE, of whom 3262 (3.4%) were aged ≥90 years. Patients aged ≥90 years were less likely to be men, and to have experienced cancer or recent surgery, but more likely to manifest immobility, chronic heart failure, anemia, renal insufficiency, or dementia than those aged <90 years. Most (99.6%) patients aged ≥90 years were receiving anticoagulant therapy. During the first 3 months, 26 patients aged ≥90 years developed VTE recurrences, 116 experienced major bleeding, and 564 died. Among patients initially presenting with pulmonary embolism (PE), deaths due to PE exceeded those due to fatal bleeding (76 vs. 19). Among those initially presenting with isolated deep-vein thrombosis (DVT), it was the reverse (2 vs. 11 deaths). CONCLUSIONS: In patients aged ≥90 years, the difference in the outcome of anticoagulant treatment depending on the initial presentation of VTE could suggest a need for different management approaches. Clinical trials evaluating the optimal duration of anticoagulation according to initial VTE presentation are warranted to limit excess deaths in this particular population.
引用
- Lafaie L, Poenou G, Hanon O, et al. Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry. J Am Geriatr Soc. 2023. PMID: 37814983. doi:10.1111/jgs.18626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。